M&A

News

Recursion Pharma and Exscientia company logos

AI biotechs Exscientia and Recursion agree $688m merger

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued

News

A pair of spectacles in front of computer screens

Does Roche have buyer's remorse for Flatiron takeover?

Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion.

News

Mallinckrodt sells Therakos unit on at a discount

Ireland-headquartered pharma group Mallinckrodt has agreed to divest its subsidiary Therakos to private equity firm CVC Capital Partners for $925 million, well below the $1.33 billion it pa

News

Anne Wojcicki, CEO and co-founder of 23andMe

23andMe board rebuffs CEO plan to take the firm private

A proposal by 23andMe founder and chief executive Anne Wojcicki to take the genetic testing company private has been rejected by a special committee of the board of directors.

R&D

Collaborative visual illustration, shaking hands in business deal

Closed and Collaborative: Mergers, acquisitions, and partner...

Welcome to a new pharmaphorum round-up.

News

Otsuka buys Jnana and PKU drug in $1.1bn deal

Japan's Otsuka Pharma has agreed to take control of US biotech Jnana Therapeutics in a deal that will give it rights to a clinical-stage candidate for the rare metabolic disorder phenylketo

AI biotechs Exscientia and Recursion agree $688m merger

Does Roche have buyer's remorse for Flatiron takeover?

Mallinckrodt sells Therakos unit on at a discount

23andMe board rebuffs CEO plan to take the firm private

Closed and Collaborative: Mergers, acquisitions, and partner...

Otsuka buys Jnana and PKU drug in $1.1bn deal

Are Makary's priority review vouchers about to be canned?

Securing your ROI: Turning post-acquisition integration into...

M&A

Editor's Picks